
TOI Stock Forecast & Price Target
TOI Analyst Ratings
Bulls say
Oncology Institute is experiencing strong financial performance and its evidence-based approach to integrated care delivery, backed by its expanding presence and utilization of technology, positions the company for future growth. Additionally, its Specialty Pharmacy segment generates significant revenue through its payment arrangements. However, competition and high debt remain potential risks to the company's success in the value-based oncology care market. Regardless, TOI is seen as a promising solution to mitigate rising oncology costs and is expected to achieve financial stability in the near future.
Bears say
Oncology Institute is facing a tough market environment with potential challenges from payors struggling with oncology inpatient and Part B spend. While the company has potential for growth with its delegated and capitated contracts, the current market conditions and the company's historically low margins make it difficult to achieve profitability in the short term. The company's high debt levels and potential need for equity financing in the future are also potential concerns for investors.
This aggregate rating is based on analysts' research of The Oncology Institute and is not a guaranteed prediction by Public.com or investment advice.
TOI Analyst Forecast & Price Prediction
Start investing in TOI
Order type
Buy in
Order amount
Est. shares
0 shares